Fig 1: VCAM‐1 and ICAM‐1 high were correlated with raised accumulating MACE rate in STEMI patients. Association between VCAM‐1 high and accumulating MACE rate (A); linkage between ICAM‐1 high and accumulating MACE rate (B) in STEMI patients.
Fig 2: VCAM‐1 and ICAM‐1 were upregulated in STEMI patients than HCs. Comparison of VCAM‐1 in STEMI patients vs. HCs (A); the value of VCAM‐1 for distinguishing STEMI patients from HCs (B); comparison of ICAM‐1 in STEMI patients vs. HCs (C); the capacity of ICAM‐1 for discriminating STEMI patients from HCs (D).
Fig 3: Modeled SARS-CoV-2 infection alters VMO transcriptomic profiles. In the VMO, qPCR analysis of pro-inflammatory markers (A) ICAM-1, (B) VCAM-1, and (C) IL-6 for perfused vascularized micro-organ (VMO) that have been treated with SARS-CoV-2 pseudotyped virus (pseudovirus), recombinant angiotensin II (rAngII) or both for 48 h. *<0.05, **<0.01, ***<0.001.
Supplier Page from Abcam for Human ICAM1 ELISA Kit, Fluorescent